Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is a clinical-stage biopharmaceutical company with a promising pipeline of drug candidates, including zidesamtinib, neladalkib, and NVL-330, all of which have shown positive results and potential for significant revenue. Despite potential risks to its valuation, Nuvalent has a strong financial position and is well-positioned to enter the market with its targeted therapies for cancer treatment. Potential competition and reimbursement challenges should also be considered, as they could impact the success and market potential of Nuvalent's products.

Bears say

Nuvalent is facing several challenges in the near future, including potential competition from other precision oncology companies and risks related to product commercialization and supply chain. In addition, Nuvalent's financials may be negatively impacted if their lead candidates, neladalkib and zidesamtinib, do not gain FDA approval or fail to meet projected peak revenue estimates. Overall, the uncertainty surrounding Nuvalent's future success in the competitive biopharmaceutical market leads to a negative outlook for the company's stock.

Nuvalent (NUVL) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 16 analysts, Nuvalent (NUVL) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.